EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquired by PERKINELMER
Context
PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally. The strategic rationale includes leveraging EUROIMMUN’s high-growth profile (averaging 19% revenue growth over five years) to accelerate PerkinElmer’s overall earnings. Additionally, the acquisition allows PerkinElmer to drive EUROIMMUN’s specialized solutions through its well-established U.S. commercial channels.
EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS, which reported an EBITDA margin of in 2017, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
EUROIMMUN is a global leader in autoimmune testing and an emerging provider of infectious disease and allergy diagnostics. Headquartered in Europe, the organization leverages deep expertise across immunology, cell biology, biochemistry, and molecular biology to develop advanced detection technologies. It manufactures high-quality diagnostic reagents and instruments used by medical laboratories worldwide to accurately identify antibodies and diagnose a wide array of conditions. Boasting a massive international footprint, the enterprise generates the vast majority of its revenue overseas, particularly across Asian and EMEA markets, serving customers in dozens of countries. Supported by a large global workforce and a decades-long history of continuous scientific innovation, the firm stands as a premier technological pillar in the specialized in-vitro diagnostics sector.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2018 | Zoetis | Abaxis | UNITED STATES | Diagnostic Equipment |
| 05/2018 | NN | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 10/2017 | CVC | SEBIA | FRANCE | Diagnostic Equipment |
| 10/2017 | UI INVESTISSEMENT / BPIFRANCE | THERADIAL | FRANCE | Medical Devices |
| 09/2017 | FRESENIUS | NXSTAGE MEDICAL | UNITED STATES | Diagnostic Equipment |
| 06/2017 | EQT PARTNERS | OTTOBOCK | GERMANY | Implants & Prosthetics |
| 06/2017 | CHARTERHOUSE | SERB | BELGIUM | Pharma & Biotech |
| 05/2017 | PAI PARTNERS | ELITECH GROUP | FRANCE | Diagnostic Equipment |
| 04/2017 | BAIN CAPITAL / CINVEN | STADA | GERMANY | Generics / Labs |
| 04/2017 | NORDSON CORPORATION | VENTION ADVANCED TECHNOLOGIES | UNITED KINGDOM | Medical Devices |
REFERENCES
Valuation range: EV 1b - 4b USD
Revenue range: 250M - 500M USD
EBITDA range: 50M - 100M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS by PERKINELMER are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: euroimmun medical laboratory diagnostics
Acquirer: perkinelmer